Kindeva Drug Delivery (Altaris) Acquires Summit Biosciences
January 18, 2024
Kindeva Drug Delivery, an operating company of healthcare investor Altaris, has acquired Summit Biosciences from its founding family shareholders. The acquisition adds Summit’s FDA- and EMA-approved 55,000 sq. ft. cGMP intranasal CDMO facility in Lexington, Kentucky, expanding Kindeva’s nasal drug‑delivery platform and global manufacturing footprint.
- Buyers
- Kindeva Drug Delivery, Altaris, LLC
- Targets
- Summit Biosciences, Inc.
- Sellers
- Founding family shareholders
- Platforms
- Kindeva Drug Delivery
- Industry
- Medical Devices
- Location
- Kentucky, United States
- Transaction Type
- Addon
Explore More
Related Acquisitions
-
Altaris Combines Kindeva Drug Delivery and Meridian Medical Technologies
December 13, 2022
Medical Devices
Altaris has completed the combination of its portfolio companies Kindeva Drug Delivery and Meridian Medical Technologies into a single, global drug‑device CDMO that will operate under the Kindeva name. The combined company expands capabilities across parenteral, inhalation, transdermal and intradermal delivery formats; Milton Boyer (formerly Meridian CEO) will lead the combined business.
-
Altaris Capital Partners Acquires Kindeva Drug Delivery from 3M
May 1, 2020
Medical Devices
Altaris Capital Partners has acquired Kindeva Drug Delivery L.P. (formerly 3M Drug Delivery Systems) from 3M Company for $650 million in a corporate carve-out transaction. Monroe Capital provided financing and an equity co-investment to support the deal, and 3M will retain a minority interest alongside Altaris as Kindeva operates independently to pursue growth and capital investments.
-
Altaris Capital Partners Acquires Meridian Medical Technologies from Pfizer
December 30, 2021
Medical Devices
Altaris Capital Partners has entered into an agreement to acquire Meridian Medical Technologies from Pfizer. Meridian, a pioneer in emergency response drug-device combination products and auto-injectors with facilities in St. Louis, Missouri and Columbia, Maryland and more than 750 employees, will become an Altaris portfolio company to expand the firm's capabilities in medical countermeasures and emergency response solutions.
-
Altaris Acquires Minaris Regenerative Medicine from Resonac
September 23, 2024
Healthcare Services
Altaris, LLC has acquired Minaris Regenerative Medicine from Resonac Corporation, making Minaris a wholly owned portfolio company of Altaris. Minaris is a cell therapy CDMO with six facilities across the United States, Germany and Japan and more than 500 employees; the deal advances Altaris' strategic initiative to build capabilities in cell and gene therapy manufacturing.
-
Biogen Acquires Alcyone Therapeutics
September 19, 2025
Medical Devices
Biogen has acquired Alcyone Therapeutics to obtain the ThecaFlex DRx intrathecal drug‑delivery system, integrating Alcyone employees into Biogen’s product delivery solutions team. Alcyone will receive $85 million upfront plus contingent milestone payments; Biogen will handle development, commercialization and manufacturing of ThecaFlex DRx while Alcyone’s remaining therapeutic assets are being divested into Neela Therapeutics.
-
TransMedics Acquires Summit Aviation to Expand Transplant Aviation Capabilities
August 1, 2023
Transportation
TransMedics Group, Inc. has signed a definitive agreement (and subsequently completed) to acquire Summit Aviation, a U.S. charter flight operator, to establish TransMedics Aviation and provide dedicated air logistics for organ transplantation. The acquisition brings Summit's charter expertise and team (founder Ben Walton to join TransMedics as VP of Aviation Services) to support TransMedics' National OCS Program and expand its organ transport capabilities nationwide.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.